Morningstar

Morningstar, Inc.

Equity Bottom-Up

Incyte's first-quarter results were in line with our expectations, and after adjusting for lower expected Olumiant royalties and the advancement of ruxolitinib cream into a second late-stage indication, we're maintaining our $97 per share fair value estimate. Incyte reported 20% growth in Jakafi, driven mostly by volume, and we're keeping our full-year estimates for Incyte revenue at $1.63 billion. We're slightly adjusting down our estimate for research and development costs for the year and…

<p>Incyte's lead drug, Jakafi, initially gained traction in 2011 as the only drug approved for severe myelofibrosis, a rare blood disorder. Jakafi's monopoly on the MF market is likely to continue, especially after two leading competitor drugs have left the playing field after lackluster pivotal trial data. Incyte expanded Jakafi’s label to polycythemia vera in late 2014 and is evaluating the drug in essential thrombocythemia and steroid refractory acute graft versus host disease, which should push…</p>

United States

Incyte Corp is a biopharmaceutical company. The Company discovers, develops and commercializes proprietary small molecule drugs, primarily used in oncology.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00